Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00

Key Points

• Morgan Stanley has raised its price target for Alnylam Pharmaceuticals from $405.00 to $475.00, indicating a potential upside of 4.81% from the stock's current price.
• Other analysts have also increased their price targets, with Scotiabank setting it at $450.00 and Barclays at $460.00, reflecting strong confidence in the stock.
• Alnylam Pharmaceuticals reported a $0.32 earnings per share (EPS), significantly surpassing analysts' expectations of a loss of ($0.54), indicating positive financial momentum.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective increased by Morgan Stanley from $405.00 to $475.00 in a report released on Monday,Benzinga reports. The brokerage presently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective would indicate a potential upside of 4.81% from the stock's current price.

A number of other equities analysts also recently weighed in on the stock. Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research note on Friday, August 1st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Stifel Nicolaus increased their price objective on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $448.04.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $3.16 during midday trading on Monday, reaching $453.19. 48,479 shares of the company were exchanged, compared to its average volume of 977,502. The company has a market capitalization of $59.40 billion, a price-to-earnings ratio of -183.78 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm's 50-day simple moving average is $441.57 and its 200-day simple moving average is $339.95. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period last year, the company earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling

In other news, Director Colleen F. Reitan sold 18,000 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company's stock, valued at approximately $362,390. This represents a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director owned 16,804 shares in the company, valued at $7,561,800. The trade was a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock valued at $44,160,261 over the last 90 days. 1.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.8% during the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock worth $4,336,064,000 after buying an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after purchasing an additional 185,783 shares during the period. Geode Capital Management LLC grew its position in Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock valued at $779,857,000 after buying an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd increased its stake in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.